Literature DB >> 8609928

Impairment of muscle mitochondrial oxidative metabolism in McArdles's disease.

N De Stefano1, Z Argov, P M Matthews, G Karpati, D L Arnold.   

Abstract

Impairment of muscle glycogenolysis in McArdle's disease (myophosphorylase deficiency) leads to exercise intolerance and exercise-induced myalgia. The pathophysiology of these symptoms is not entirely clear. We used phosphorus magnetic resonance spectroscopy to measure muscle phosphate metabolite concentrations and intracellular pH during brief ischemic exercise and in the period of aerobic metabolic recovery after exercise, with special attention to cytoplasmic adenosine 5'-diphosphate (ADP). In 5 patients with McArdle's disease, calculated muscle intracellular ADP concentrations at the beginning of recovery were higher than in normal control subjects (70-425 mmol/L, control mean: 73 +/- 40 mmol/L, P < 0.05). The half-time for intracellular ADP recovery after exercise, an index of maximal mitochondrial oxidative phosphorylation, was 0.16 +/- 0.07 in normal controls and was independent of metabolic state or intracellular pH. ADP recoveries were abnormally slow in all patients with McArdle's disease (range: 0.32-0.83 min, mean = 0.2 min, P < 0.0001). These results are indicative of a limitation in the rate of oxidative phosphorylation in muscle of patients with McArdle's disease, most likely due to impaired substrate delivery to mitochondria. This impairment of mitochondrial function may contribute to the exercise-related symptoms in McArdle's disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8609928     DOI: 10.1002/(SICI)1097-4598(199606)19:6<764::AID-MUS12>3.0.CO;2-L

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  9 in total

Review 1.  Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).

Authors:  Rosaline Quinlivan; Andrea Martinuzzi; Benedikt Schoser
Journal:  Cochrane Database Syst Rev       Date:  2014-11-12

Review 2.  Pharmacological and nutritional treatment trials in McArdle disease.

Authors:  R M Quinlivan; R J Beynon
Journal:  Acta Myol       Date:  2007-07

Review 3.  McArdle disease: a unique study model in sports medicine.

Authors:  Alfredo Santalla; Gisela Nogales-Gadea; Niels Ørtenblad; Astrid Brull; Noemi de Luna; Tomàs Pinós; Alejandro Lucia
Journal:  Sports Med       Date:  2014-11       Impact factor: 11.136

Review 4.  Magnetic resonance spectroscopy in vivo: applications in neurological disorders.

Authors:  D L Arnold; N De Stefano
Journal:  Ital J Neurol Sci       Date:  1997-12

5.  Specific ATPases drive compartmentalized glycogen utilization in rat skeletal muscle.

Authors:  Joachim Nielsen; Peter Dubillot; Marie-Louise H Stausholm; Niels Ørtenblad
Journal:  J Gen Physiol       Date:  2022-07-07       Impact factor: 4.000

Review 6.  Muscle fatigue during high-intensity exercise in children.

Authors:  Sébastien Ratel; Pascale Duché; Craig A Williams
Journal:  Sports Med       Date:  2006       Impact factor: 11.928

7.  Altered mitochondrial oxidative phosphorylation capacity in horses suffering from polysaccharide storage myopathy.

Authors:  Irene Tosi; Tatiana Art; Dominique Cassart; Frédéric Farnir; Justine Ceusters; Didier Serteyn; Hélène Lemieux; Dominique-Marie Votion
Journal:  J Bioenerg Biomembr       Date:  2018-08-24       Impact factor: 2.945

Review 8.  Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components.

Authors:  Richard Myles Turner; Munir Pirmohamed
Journal:  J Clin Med       Date:  2019-12-20       Impact factor: 4.241

Review 9.  Preclinical Research in McArdle Disease: A Review of Research Models and Therapeutic Strategies.

Authors:  Mónica Villarreal-Salazar; Astrid Brull; Gisela Nogales-Gadea; Antoni L Andreu; Miguel A Martín; Joaquín Arenas; Alfredo Santalla; Alejandro Lucia; John Vissing; Thomas O Krag; Tomàs Pinós
Journal:  Genes (Basel)       Date:  2021-12-28       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.